These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 24993123)
1. NOAC in acute coronary syndrome and AF? Niespialowska-Steuden M; Collins P; Costopoulos C; Gorog DA Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):154-64. PubMed ID: 24993123 [TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants in acute coronary syndrome. Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP; Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380 [TBL] [Abstract][Full Text] [Related]
4. [Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)]. Ieko M Rinsho Byori; 2014 Oct; 62(10):948-57. PubMed ID: 27526540 [TBL] [Abstract][Full Text] [Related]
5. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants: An update. Franco Moreno AI; Martín Díaz RM; García Navarro MJ Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790 [TBL] [Abstract][Full Text] [Related]
9. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
11. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459 [TBL] [Abstract][Full Text] [Related]
12. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
13. [Evidence of novel oral anticoagulants (NOAC)]. Kitazono T Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582 [TBL] [Abstract][Full Text] [Related]
15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584 [TBL] [Abstract][Full Text] [Related]
17. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. Rubboli A; Agewall S; Huber K; Lip GY Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527 [TBL] [Abstract][Full Text] [Related]
18. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation]. Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H Therapie; 2015; 70(6):485-92. PubMed ID: 26223162 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587 [TBL] [Abstract][Full Text] [Related]
20. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]